VS-5584, with the CAS number 1246560-33-7, is a small molecule inhibitor primarily known for its role in targeting the mTOR (mechanistic target of rapamycin) signaling pathway. This compound exhibits characteristics typical of a selective inhibitor, demonstrating potential therapeutic applications in oncology and other diseases associated with dysregulated mTOR activity. VS-5584 is often studied for its ability to inhibit both mTORC1 and mTORC2 complexes, which are crucial for cell growth, proliferation, and survival. The compound is characterized by its moderate solubility in organic solvents and relatively low solubility in water, which is common for many small molecule inhibitors. Its chemical structure includes specific functional groups that contribute to its binding affinity and selectivity for mTOR. Research indicates that VS-5584 may enhance the efficacy of other anticancer agents, making it a subject of interest in combination therapy studies. As with many investigational compounds, ongoing research is essential to fully elucidate its pharmacokinetics, pharmacodynamics, and potential side effects in clinical settings.

VS-5584

1246560-33-7: VS-5584, with the CAS number 1246560-33-7, is a small molecule inhibitor primarily known for its role in targeting the mTOR (mechanistic target of rapamycin) signaling pathway. This compound exhibits characteristics typical of a selective inhibitor, demonstrating potential therapeutic applications in oncology and other diseases associated with dysregulated mTOR activity. VS-5584 is often studied for its ability to inhibit both mTORC1 and mTORC2 complexes, which are crucial for cell growth, proliferation, and survival. The compound is characterized by its moderate solubility in organic solvents and relatively low solubility in water, which is common for many small molecule inhibitors. Its chemical structure includes specific functional groups that contribute to its binding affinity and selectivity for mTOR. Research indicates that VS-5584 may enhance the efficacy of other anticancer agents, making it a subject of interest in combination therapy studies. As with many investigational compounds, ongoing research is essential to fully elucidate its pharmacokinetics, pharmacodynamics, and potential side effects in clinical settings.

5-[9-Isopropyl-8-methyl-2-(morpholin-4-yl)purin-6-yl]pyrimidin-2-amine

<p>VS-5584 (SB2343) is a pan-PI3K/mTOR kinase inhibitor.</p>

CAS 1246560-33-7

VS-5584

5-[9-Isopropyl-8-methyl-2-(morpholin-4-yl)purin-6-yl]pyrimidin-2-amine

Ref: IN-DA000MK4

VS-5584

Ref: 54-BUP10382

VS-5584

Ref: TM-T6103